Drug/Device Combo Hits Phase III Endpoint
AcelRx Moving Sublingual Analgesic Toward Goal Line
By Marie Powers
Thursday, November 15, 2012
After nearly five years, specialty pharma AcelRx Pharmaceuticals Inc. reported a breakthrough with positive top-line data from the first Phase III study of its lead product candidate, the sublingual Sufentanil NanoTab PCA System (ARX-01), compared to intravenous morphine in postoperative pain.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.